Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sara A Hurvitz, MD
Head of Hematology and Oncology Division, Fred Hutchinson Cancer Center, Seattle, WA (United States)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Complejo Hospitalario Universitario A Coruña (chuac)
A Coruña, Spain
- Hospital Universitari Dexeus
Barcelona, Spain
- Hospital Universitari Vall D'Hebron
Barcelona, Spain
- Institut Català D' Oncologia Girona (ico)
Girona, Spain
- Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
- Hospital Beata María Ana
Madrid, Spain
- Hospital Cínico San Carlos
Madrid, Spain
- Hospital Universitario de Navarra
Pamplona, Spain
- Complejo Hospitalario Universitario de Santiago (chus)
Santiago de Compostela, Spain
- Hospital Universitario Virgen del Rocío
Seville, Spain
- Hospital Arnau de Vilanova de Valencia
Valencia, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 May 2025
- Primary completion
- 31 Aug 2026
- Completion
- 31 Aug 2026
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 31
- Registry id
- NCT06604858
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.